Zytoprotec is a biotech company that specialises in "cell protection/cell repair" and was founded in February 2007. The company is currently focussing on cytoprotection with the first innovative product for renal therapies: PD-protec™. PD-protec™ is entering the second clinical phase in 2012.
The lives of millions of people/patients with renal failure worldwide can be saved/improved long-term or extended until transplantation by these patent-protected research results.
Potential global sales 6 years after launch are expected to amount to more than EUR 1 billion.
Additional specific research in the field of cytoprotection is already successfully under way and has led to another patent application at the beginning of 2012. The research pipeline is focussed on diabetes and hypertension.
The goal of the company is "To become the leading cell repair company!" in ten years' time.
Company ID: 158400 - GW ID(s): 23716
